Literature DB >> 23215859

Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.

Arnold S Bayer1, Tanja Schneider, Hans-Georg Sahl.   

Abstract

The bactericidal, cell membrane-targeting lipopeptide antibiotic daptomycin (DAP) is an important agent in treating invasive Staphylococcus aureus infections. However, there have been numerous recent reports of development of daptomycin resistance (DAP-R) during therapy with this agent. The mechanisms of DAP-R in S. aureus appear to be quite diverse. DAP-R strains often exhibit progressive accumulation of single nucleotide polymorphisms in the multipeptide resistance factor gene (mprF) and the yycFG components of the yycFGHI operon. Both loci are involved in key cell membrane (CM) events, with mprF being responsible for the synthesis and outer CM translocation of the positively charged phospholipid, lysyl-phosphotidylglycerol (L-PG), while the yyc operon is involved in the generalized response to stressors such as antimicrobials. In addition, other perturbations of the CM have been identified in DAP-R strains, including extremes in CM order, resistance to CM depolarization and permeabilization, and reduced surface binding of DAP. Moreover, modifications of the cell wall (CW) appear to also contribute to DAP-R, including enhanced expression of the dlt operon (involved in d-alanylation of CW teichoic acids) and progressive CW thickening.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23215859      PMCID: PMC3556211          DOI: 10.1111/j.1749-6632.2012.06819.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  123 in total

1.  Chemoenzymatic design of acidic lipopeptide hybrids: new insights into the structure-activity relationship of daptomycin and A54145.

Authors:  Florian Kopp; Jan Grünewald; Christoph Mahlert; Mohamed A Marahiel
Journal:  Biochemistry       Date:  2006-09-05       Impact factor: 3.162

2.  Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

3.  Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci.

Authors:  Vera Sass; Tanja Schneider; Miriam Wilmes; Christian Körner; Alessandro Tossi; Natalia Novikova; Olga Shamova; Hans-Georg Sahl
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

4.  Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.

Authors:  Satish K Pillai; Howard S Gold; George Sakoulas; Christine Wennersten; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

5.  Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia.

Authors:  Eun Young Choi; Jin Won Huh; Chae-Man Lim; Younsuck Koh; Sung-Han Kim; Sang-Ho Choi; Yang Soo Kim; Mi-Na Kim; Sang-Bum Hong
Journal:  Intensive Care Med       Date:  2011-01-21       Impact factor: 17.440

6.  The virulence regulator Sae of Staphylococcus aureus: promoter activities and response to phagocytosis-related signals.

Authors:  Tobias Geiger; Christiane Goerke; Markus Mainiero; Dirk Kraus; Christiane Wolz
Journal:  J Bacteriol       Date:  2008-03-14       Impact factor: 3.490

7.  Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.

Authors:  José M Miró; Cristina García-de-la-Mària; Yolanda Armero; Elisa de-Lazzari; Dolors Soy; Asunción Moreno; Ana del Rio; Manel Almela; Carlos A Mestres; José M Gatell; María-Teresa Jiménez-de-Anta; Francesc Marco
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

8.  Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.

Authors:  Michael M Mwangi; Shang Wei Wu; Yanjiao Zhou; Krzysztof Sieradzki; Herminia de Lencastre; Paul Richardson; David Bruce; Edward Rubin; Eugene Myers; Eric D Siggia; Alexander Tomasz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

9.  Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.

Authors:  Nicole Cotroneo; Robert Harris; Nancy Perlmutter; Terry Beveridge; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

10.  The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion.

Authors:  Christoph M Ernst; Petra Staubitz; Nagendra N Mishra; Soo-Jin Yang; Gabriele Hornig; Hubert Kalbacher; Arnold S Bayer; Dirk Kraus; Andreas Peschel
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

View more
  116 in total

1.  A liaR deletion restores susceptibility to daptomycin and antimicrobial peptides in multidrug-resistant Enterococcus faecalis.

Authors:  Jinnethe Reyes; Diana Panesso; Truc T Tran; Nagendra N Mishra; Melissa R Cruz; Jose M Munita; Kavindra V Singh; Michael R Yeaman; Barbara E Murray; Yousif Shamoo; Danielle Garsin; Arnold S Bayer; Cesar A Arias
Journal:  J Infect Dis       Date:  2014-10-31       Impact factor: 5.226

Review 2.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

Review 3.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

4.  Daptomycin Resistance and Tolerance Due to Loss of Function in Staphylococcus aureus dsp1 and asp23.

Authors:  Elaine M Barros; Melissa J Martin; Elizabeth M Selleck; François Lebreton; Jorge Luiz M Sampaio; Michael S Gilmore
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

5.  Case Commentary: Daptomycin Resistance in Staphylococcus argenteus-from Northern Australia to San Francisco.

Authors:  Arnold S Bayer; Steven Y C Tong
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

6.  Impact of Bacterial Membrane Fatty Acid Composition on the Failure of Daptomycin To Kill Staphylococcus aureus.

Authors:  Rym Boudjemaa; Clément Cabriel; Florence Dubois-Brissonnet; Nicolas Bourg; Guillaume Dupuis; Alexandra Gruss; Sandrine Lévêque-Fort; Romain Briandet; Marie-Pierre Fontaine-Aupart; Karine Steenkeste
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

7.  Novel method to identify the optimal antimicrobial peptide in a combination matrix, using anoplin as an example.

Authors:  J K Munk; C Ritz; F P Fliedner; N Frimodt-Møller; P R Hansen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

8.  Identification of 5,6-dihydroimidazo[2,1-b]thiazoles as a new class of antimicrobial agents.

Authors:  Yangmei Li; Nina Bionda; Renee Fleeman; Hongjie Wang; Akihiko Ozawa; Richard A Houghten; Lindsey Shaw
Journal:  Bioorg Med Chem       Date:  2016-09-12       Impact factor: 3.641

Review 9.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

10.  Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16.

Authors:  Bruk Mensa; Gabriella L Howell; Richard Scott; William F DeGrado
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.